HistoIndex brings new CEO on Board
Singapore based HistoIndex has appointed Dr Poon Thong Yuen as its new Chief Executive Officer (CEO). Dr Poon takes over from Dr Gideon Ho, who will continue to drive the global business growth of the company as the Chief Commercial Officer (CCO).
Dr Poon was most recently Chief Investment Officer of Zicom MedTacc, a Singapore-based MedTech investor that has supported various start-up companies, including HistoIndex, from product prototyping to market adoption. Zicom MedTacc is a co-investor of HistoIndex, together with SEEDS Capital (the investment arm of Enterprise Singapore).
Dr Poon is a seasoned investment professional with more than a decade of corporate experiences with healthcare services, therapeutic drugs and medical devices, including former board directorship roles in companies such as Artisan Pharma (acquired by Asahi Kasei Pharma), Inviragen (acquired by Takeda Pharmaceutical) and Forma Therapeutics (large collaboration agreement with Celgene).